| Debug Stats | ### Total Build Time: 30 ms 36.811 KB CONCEPT_NAME gt=9 ms Completed: 9 ms rowSize= 328 bytesCONCEPT_SOLR_HIT_STATS gt=0 Completed: 0 ms rowSize= 14 bytesCONCEPT_DEFINITION gt=0 Completed: 0 ms rowSize= 211 bytes- Skipping details on:
CONCEPT_SYNONYM gt=NONE 0 Completed: 0 ms rowSize= 0 bytes - Skipping details on:
CONCEPT_TEXT gt=NONE 0 Completed: 0 ms rowSize= 0 bytes CONCEPT_SEMANTIC_TYPE gt=0 Completed: 0 ms rowSize= 14 bytes- Skipping details on:
CONCEPT_NAMESPACE gt=NONE 0 Completed: 0 ms rowSize= 0 bytes CONCEPT_PARENTS gt=0 Completed: 0 ms rowSize= 7 bytesCONCEPT_CHILDREN gt=0 Completed: 0 ms rowSize= 8 bytesCONCEPT_ANCESTRAL_ROOTS gt=0 Completed: 0 ms rowSize= 15 bytesCONCEPT_RELATIONSHIPS gt=6 ms Completed: 6 ms rowSize= 3.710 KBCONCEPT_GENES gt=13 ms Completed: 13 ms rowSize= 31.354 KBCONCEPT_XREFS gt=1 ms Completed: 1 ms rowSize= 1.149 KBCONCEPT_ANCILLARY gt=1 ms Completed: 1 ms rowSize= 14 bytes- Reload Stats
|
Genes (32)
Species:
human : 31 mouse : 1 | |
| Mouse | IGFBP5 | 3488 | insulin-like growth factor binding protein 5 | Systemic administration of antisense IGFBP-5 ODN in mice bearing Shionogi tumors after castration significantly delayed time to progression to androgen independence and inhibited growth of AI recurrent tumors. | | Human | LOC652799 | 652799 | | The recurrent hepatic tumor developed a secondary point mutation (Val654Ala) in exon 13, which may be responsible for the imatinib resistance | | Human | ABCC3 | 8714 | ATP-binding cassette, sub-family C (CFTR/MRP), member 3 | We showed that the expression of MDR1, MRP1, MRP2 and MRP3 in recurrent tumors and residual tumors after chemotherapeutic treatment was higher than that in untreated primary tumors. | | Human | EIF3H | 8667 | eukaryotic translation initiation factor 3, subunit H | High-level amplification of EIF3S3 was found in 11 of 125 (9%) of pT1/pT2 tumors, 12 of 44 (27%) of pT3/pT4 tumors, and 8 of 37 (22%) of lymph node metastases as well as in 26 of 78 (33%) and 15 of 30 (50%) of hormone refractory locally recurrent tumors and metastases, respectively. | | Human | XIST | 7503 | X inactive specific transcript (non-protein coding) | In a study to compare the global RNA expression profiles between primary and recurrent ovarian tumors from the same patient, we have identified XIST (inactive X chromosome-specific transcripts) as the most differentially expressed gene that was down-regulated in the recurrent tumor. | | Human | TIMP2 | 7077 | TIMP metallopeptidase inhibitor 2 | Recurrent tumors from both groups also displayed an abnormal expression profile of the metalloproteinase, gel A, and its inhibitor, TIMP-2, consistent with their highly invasive behavior. | | Human | TGFB2 | 7042 | transforming growth factor, beta 2 | TGF-beta2 expression was detectable in 75% of primary and only 53% of recurrent tumor specimens. | | Human | TFRC | 7037 | transferrin receptor (p90, CD71) | In moderately differentiated tumors or in T1 tumors, TFR expression was higher in multiple or recurrent tumors than in simple tumors. | | Human | TFF1 | 7031 | trefoil factor 1 | Expression of pS2 protein in 50 primary tumors, metastases and recurrent tumors of colorectal carcinomas has been analyzed by immunohistochemistry. However, in metastases and recurrent tumors, pS2 expression did not differ from primary lesions (53% positive lesions). | | Human | TAP2 | 6891 | transporter 2, ATP-binding cassette, sub-family B (MDR/TAP) | Here we report that the proto-oncogene product PML induces expression of LMP-2, LMP-7, TAP-1 and TAP-2 in an MHC-class I-negative, recurrent tumour, leading to the re-expression of cell-surface MHC in tumours and to rejection of the tumours. | | Human | SYP | 6855 | synaptophysin | Histopathological examination of the recurrent tumor showed anaplastic progression with confusing immunohistochemical (IHC) results; the tumor was positive for NeuN and synaptophysin staining. | | Human | SPP1 | 6696 | secreted phosphoprotein 1 | osteopontin and IL-8 may have roles in prostate neoplasm recurrence | | Human | SDHD | 6392 | succinate dehydrogenase complex, subunit D, integral membrane protein | Eighty-four patients (all but 2 followed up for 8.8 +/- 5.7 years) with ASP (57 with adrenal tumors, 27 with extra-adrenal, multiple, malignant, or recurrent tumors) were screened for the major susceptibility genes for phaeochromocytoma (RET, VHL, SDHD, and SDHB). | | Human | PSMB9 | 5698 | proteasome (prosome, macropain) subunit, beta type, 9 | Here we report that the proto-oncogene product PML induces expression of LMP-2, LMP-7, TAP-1 and TAP-2 in an MHC-class I-negative, recurrent tumour, leading to the re-expression of cell-surface MHC in tumours and to rejection of the tumours. | | Human | PSMB8 | 5696 | proteasome (prosome, macropain) subunit, beta type, 8 | Here we report that the proto-oncogene product PML induces expression of LMP-2, LMP-7, TAP-1 and TAP-2 in an MHC-class I-negative, recurrent tumour, leading to the re-expression of cell-surface MHC in tumours and to rejection of the tumours. | | Human | PDGFB | 5155 | platelet-derived growth factor beta polypeptide | Expression of the sis gene was lower in the recurrent tumors than in the primary cases, and there was no detectable expression in anaplastic meningioma cells. | | Human | NF2 | 4771 | neurofibromin 2 (merlin) | Using paraffin-embedded archival material from 28 cHPCs (including three primary and recurrent tumors), 10 pHPCs, and 26 meningiomas, we scanned all 17 exons of the NF2 gene and flanking intronic sequences for mutations with single strand conformation polymorphism analysis and DNA sequencing. | | Human | MMP13 | 4322 | matrix metallopeptidase 13 (collagenase 3) | MMP-13 mRNAs were detected in 22 of 29 SCC cell lines: in 14 of 15 primary SCC cell lines and in 8 of 14 SCC cell lines from recurrent tumors or metastases. | | Human | MCM7 | 4176 | minichromosome maintenance complex component 7 | In addition, the 4 pairs of primary and recurrent tumors all showed changes in MCM7 expression from negative to positive, whereas none of them had MYCN amplification. | | Human | MCM2 | 4171 | minichromosome maintenance complex component 2 | Seven out of the 10 recurrent meningiomas displayed a Mcm2 LI((Max) greater than 30%, compared to 0 out of 20 for non-recurrent tumours. | | Human | IL8 | 3576 | interleukin 8 | osteopontin and IL-8 may have roles in prostate neoplasm recurrence | | Human | ID1 | 3397 | inhibitor of DNA binding 1, dominant negative helix-loop-helix protein | We found no significant association between the level of Id1 protein expression and patient age, sex, tumor-node-metastasis stage, tumor size, primary tumor vs. lymph node metastasis, primary tumor vs. recurrent tumors, and extent of tumor differentiation. | | Human | MLANA | 2315 | melan-A | Retrospective immunohistochemical staining with newly commercially available antibodies including MART-1 was done on both the original and the recurrent tumor, confirming the diagnosis of uterine PEComa. | | Human | DMBT1 | 1755 | deleted in malignant brain tumors 1 | Additional loss of heterozygosity for the 10p15 region, for PTEN, and/or for DMBT1 in the recurrent tumor was noted in 7 of 22 cases (32%), suggesting that additional inactivation of tumor suppressor genes on chromosome 10 is another important feature of glioma relapse. | | Human | CTSH | 1512 | cathepsin H | In the mandibular osteoradionecrosis group, there was a tendency for cathepsin H level to decrease, although only in cases free from recurrent tumor growth. |
|
